Stock PA8K PAION AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Paion AG Xetra

Equities

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

End-of-day quote Xetra
Other stock markets
 07:00:00 2023-10-31 pm EDT 		5-day change 1st Jan Change
0.36 EUR +4.35% Intraday chart for Paion AG -.--% -.--%
Feb. 23 Humanwell Healthcare Co.,Ltd. completed the acquisition of essential business operations of PAION AG and PAION Deutschland GmbH. CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 166.1 137.7 130.5 161 86.46 30.67
Enterprise Value (EV) 1 141.3 120.5 111.8 141.3 100.2 40.4
P/E ratio -13.3 x -13.5 x -18.5 x 81 x -3.89 x -53 x
Yield - - - - - -
Capitalization / Revenue 28.6 x 49.8 x 16.3 x 8.19 x 12.1 x 0.92 x
EV / Revenue 24.3 x 43.5 x 14 x 7.19 x 14.1 x 1.22 x
EV / EBITDA - -9,780,499 x -13,123,008 x 59,061,867 x -5,109,342 x 12,507,746 x
EV / FCF -8.93 x -11.3 x 39.6 x -27.2 x -3.15 x 11.4 x
FCF Yield -11.2% -8.89% 2.53% -3.67% -31.7% 8.78%
Price to Book 6.59 x 6.62 x 8.86 x 7.56 x 12.4 x 4.64 x
Nbr of stocks (in thousands) 6,108 6,374 6,427 6,624 7,134 7,134
Reference price 2 27.20 21.60 20.30 24.30 12.12 4.300
Announcement Date 3/22/18 3/20/19 3/26/20 3/30/21 3/30/22 5/31/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 5.811 2.766 8 19.66 7.128 33.25
EBITDA - -12.32 -8.516 2.393 -19.62 3.23
EBIT 1 -15.9 -12.46 -9.326 1.583 -22.19 2.22
Operating Margin -273.61% -450.31% -116.57% 8.05% -311.34% 6.68%
Earnings before Tax (EBT) 1 -15.85 -12.45 -9.448 1.43 -22.58 -0.201
Net income 1 -12.09 -9.939 -7.016 2.222 -21.79 -0.579
Net margin -208.11% -359.36% -87.7% 11.31% -305.62% -1.74%
EPS 2 -2.046 -1.600 -1.100 0.3000 -3.114 -0.0812
Free Cash Flow 1 -15.82 -10.71 2.825 -5.188 -31.81 3.545
FCF margin -272.25% -387.05% 35.31% -26.39% -446.28% 10.66%
FCF Conversion (EBITDA) - - - - - 109.77%
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/22/18 3/20/19 3/26/20 3/30/21 3/30/22 5/31/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - 13.8 9.72
Net Cash position 1 24.8 17.2 18.7 19.6 - -
Leverage (Debt/EBITDA) - - - - -0.7019 x 3.01 x
Free Cash Flow 1 -15.8 -10.7 2.82 -5.19 -31.8 3.55
ROE (net income / shareholders' equity) -48.2% -43.2% -39.5% 12.3% -154% -8.51%
ROA (Net income/ Total Assets) -28.4% -27.7% -23.7% 3.73% -42.7% 3.7%
Assets 1 42.51 35.88 29.63 59.6 50.99 -15.64
Book Value Per Share 2 4.130 3.260 2.290 3.210 0.9800 0.9300
Cash Flow per Share 2 4.060 2.700 2.920 2.970 0.9000 1.490
Capex 1 0.02 0.01 0.02 0.01 19.2 1.59
Capex / Sales 0.43% 0.47% 0.19% 0.07% 269.42% 4.77%
Announcement Date 3/22/18 3/20/19 3/26/20 3/30/21 3/30/22 5/31/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PA8K Stock
  4. PA8K Stock
  5. Financials Paion AG